Detalles de la búsqueda
1.
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
N Engl J Med
; 383(15): 1425-1435, 2020 10 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32966714
2.
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
Diabetes Obes Metab
; 24(7): 1245-1254, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35266296
3.
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Circulation
; 142(23): 2205-2215, 2020 12 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33026243
4.
Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
Diabetes Obes Metab
; 23(7): 1640-1651, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33769675
5.
A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control.
Diabetes Obes Metab
; 23(6): 1242-1251, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33512755
6.
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
Diabetologia
; 63(6): 1128-1140, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32236732
7.
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
Diabetes Obes Metab
; 22(4): 574-582, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31797522
8.
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies.
Diabetes Obes Metab
; 22(12): 2276-2286, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32700421
9.
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Diabetes Obes Metab
; 21(4): 781-790, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30393950
10.
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
Eur Heart J
; 44(48): 5163-5166, 2023 Dec 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37864578
11.
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
Cardiovasc Diabetol
; 16(1): 112, 2017 09 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28893244
12.
A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.
Diabetes Obes Metab
; 19(11): 1602-1609, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28449368
13.
Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Diabetes Obes Metab
; 19(3): 394-400, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28093853
14.
A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
BMC Endocr Disord
; 17(1): 70, 2017 Nov 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29110647
15.
A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.
Int J Clin Pract
; 71(6)2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28449320
16.
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
Cell Metab
; 7(1): 68-78, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18177726
17.
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
J Clin Endocrinol Metab
; 108(8): 2042-2051, 2023 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36702781
18.
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
Cell Metab
; 4(4): 275-82, 2006 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17011500
19.
Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV.
Diabetes Ther
; 12(5): 1279-1297, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33721213
20.
Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV.
Diabetes Ther
; 12(4): 1175-1192, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33694093